公开(公告)号：US10125137B2

公开(公告)日：2018-11-13

申请号：US15551015

申请日：2016-02-17

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Tao Wang ,  Zhiwei Yin ,  John F. Kadow

IPC分类号： C07D487/04 ,  C07D405/10 ,  C07D471/04 ,  C07D487/10 ,  A61K45/06 ,  A61K31/4025 ,  A61K31/4162 ,  A61K31/4188 ,  A61K31/407 ,  A61K31/437

摘要： Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV: Formula (I).

公开(公告)号：US20170101416A1

公开(公告)日：2017-04-13

申请号：US15312022

申请日：2015-05-19

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Tao WANG ,  Zhongxing Zhang ,  John F. Kadow

IPC分类号： C07D491/048 ,  C07D405/10

CPC分类号： C07D491/048 ,  C07D307/84 ,  C07D405/10

摘要： Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: formula (I).

公开(公告)号：US20150329543A1

公开(公告)日：2015-11-19

申请号：US14725318

申请日：2015-05-29

申请人： Bristol-Myers Squibb Company

发明人： Tao Wang ,  Zhongxing Zhang ,  Nicholas A. Meanwell ,  John F. Kadow ,  Zhiwei Yin ,  Qiufen May Xue ,  Alicia Regueiro-Ren ,  John D. Matiskella ,  Yasutsugu Ueda

IPC分类号： C07D471/04

CPC分类号： C07D471/04 ,  A61K31/496 ,  A61K45/06 ,  C07D491/048

摘要： This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

摘要翻译： 本发明提供具有药物和生物影响性质的化合物，其药物组合物和使用方法。 特别地，本发明涉及氮杂吲哚乙酰基哌嗪衍生物。 这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药，抗感染剂，免疫调节剂或HIV进入抑制剂组合使用。 更具体地说，本发明涉及艾滋病毒和艾滋病的治疗。

公开(公告)号：US20150210684A1

公开(公告)日：2015-07-30

申请号：US14419559

申请日：2013-08-07

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Tao Wang ,  Zhongxing Zhang ,  John F. Kadow ,  Nicholas A. Meanwell ,  Edward H. Ruediger ,  Clint A. James ,  Daniel H. Deon ,  David J. Carini ,  Barry L. Johnson

IPC分类号： C07D471/04 ,  A61K45/06 ,  A61K31/4545 ,  C07D401/06 ,  A61K31/454

CPC分类号： C07D471/04 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  C07D401/06

摘要： Compounds of Formula I, including pharmaceutically acceptable salts thereof: formule (I): wherein A is selected from the group consisting of: formule (II) and wherein Z is selected from the group consisting of: formule (III): and. are useful as HIV attachment inhibitors.

摘要翻译： 式I化合物，包括其药学上可接受的盐：式（I）：其中A选自：结构（II），并且其中Z选自：基团（III）：和。 可用作HIV附着抑制剂。

公开(公告)号：US20150025240A1

公开(公告)日：2015-01-22

申请号：US14249638

申请日：2014-04-10

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Yasutsugu Ueda ,  Timothy P. Connolly ,  John F. Kadow ,  Nicholas A. Meanwell ,  Tao Wang ,  Chung-Pin H. Chen ,  Kap-Sun Yeung ,  Zhongxing Zhang ,  David Kenneth Leahy ,  Shawn K. Pack ,  Nachimuthu Soundararajan ,  Pierre Sirard ,  Kathia Levesque ,  Dominique Thoraval

IPC分类号： C07F9/06 ,  C07F9/6561

CPC分类号： A61K31/675 ,  A61K31/497 ,  A61K31/519 ,  A61K45/06 ,  C07C215/10 ,  C07D471/04 ,  C07F9/062 ,  C07F9/5728 ,  C07F9/65515 ,  C07F9/65586 ,  C07F9/6561

摘要： This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

公开(公告)号：US20140275154A1

公开(公告)日：2014-09-18

申请号：US14204292

申请日：2014-03-11

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Kyle J. Eastman ,  Kyle E. Parcella ,  John F. Kadow

IPC分类号： C07D491/048

CPC分类号： C07D491/048 ,  C07D491/04

摘要： The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

摘要翻译： 本公开提供式I化合物，包括其盐，以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。

公开(公告)号：US08722688B2

公开(公告)日：2014-05-13

申请号：US13798286

申请日：2013-03-13

申请人： Bristol-Myers Squibb Company

发明人： Kap-Sun Yeung ,  Kyle E. Parcella ,  John A. Bender ,  Brett R. Beno ,  Katharine A. Grant-Young ,  Ying Han ,  Piyasena Hewawasam ,  John F. Kadow ,  Andrew Nickel

IPC分类号： A61K31/506

CPC分类号： A61K31/506 ,  A61K45/06 ,  C07D307/84 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12 ,  C07D453/00 ,  C07D491/10

摘要： The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

摘要翻译： 本公开提供式I化合物，包括其盐，以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。

公开(公告)号：US20140018389A1

公开(公告)日：2014-01-16

申请号：US14027531

申请日：2013-09-16

申请人： Bristol-Myers Squibb Company

发明人： Rico Lavoie ,  John A. Bender ,  Jeffrey Lee Romine ,  Edward H. Ruediger ,  Carol Bachand ,  Omar D. Lopez ,  Qi Chen ,  Makonen Belema ,  John F. Kadow ,  Lawrence G. Hamann

IPC分类号： C07D417/14 ,  C07D405/14 ,  C07D401/14 ,  C07D403/14 ,  C07D409/14 ,  C07D413/14

CPC分类号： C07D417/14 ,  C07D401/14 ,  C07D403/06 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/10 ,  C07D419/10 ,  C07D493/08

摘要： This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

摘要翻译： 本公开涉及式（I）的新化合物或说明书中定义的和包含这些新化合物的组合物。 这些化合物是有用的抗病毒剂，特别是抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白的功能。 因此，本公开还涉及通过使用这些新化合物或包含这些新化合物的组合物治疗HCV相关疾病或病症的方法。

公开(公告)号：US10125111B2

公开(公告)日：2018-11-13

申请号：US15551002

申请日：2016-02-17

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Tao Wang ,  Zhiwei Yin ,  Zhongxing Zhang ,  John F. Kadow

IPC分类号： C07D307/82 ,  C07D307/84 ,  C07D405/04 ,  C07D405/12

摘要： Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus, (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US10087167B2

公开(公告)日：2018-10-02

申请号：US15551012

申请日：2016-02-17

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Tao Wang ,  Zhiwei Yin ,  John F. Kadow

IPC分类号： C07D405/10 ,  A61P31/14 ,  C07D405/12 ,  C07D417/14 ,  C07D413/14 ,  C07D405/14 ,  C07D307/84

摘要： Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and areuseful in treating those infected with HCV.